Trump administration allocates $50 million to psychedelic research and moves to downgrade medical marijuana
President Trump signed an executive order that earmarks $50 million for research into psychedelics as potential mental‑health treatments and directs the FDA to accelerate their review process.
The administration also announced that medical marijuana will be removed from the highest controlled‑substance schedule and is urging the Drug Enforcement Administration to apply the same downgrade to recreational cannabis.
These policy shifts contrast with the administration's hardline approach to fentanyl, signaling a broader change in Republican drug policy that could affect pharmaceutical development and investment strategies.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Trump’s boosting of psychedelics, cannabis signal a new era in GOP drug policy”
read at STAT ↗
comments(0)
5-min edit window · permanent after that